Thursday, Jan. 20, 2022

‘Ultrapotent’ Antibodies Neutralize SARS-CoV-2 Variants in NIAID Study

_{Caption: This transmission electron micrograph shows a SARS-CoV-2 virus particle (Alpha variant UK B.1.1.7), isolated from a patient sample and cultivated in cell culture. The prominent projections (red) seen on the outside of the virus particle (blue) are spike proteins. Credit: NIAID}

NIAID scientists have developed an array of monoclonal antibodies from recovered COVID-19 patients, and two of the therapeutic treatments in a recent study neutralized a variety of disease-causing virus variants. The study, not peer reviewed but posted on medRxiv, shows that the monoclonal antibodies have “ultrapotent neutralizing activity” against SARS-CoV-2, the virus that causes COVID-19. One of the treatments, NE12, was effective at neutralizing the original virus strain in the United States, WA-1, as well as the Alpha and Delta variants that emerged. A second treatment, NA8, neutralized the Beta and Omicron variants. The scientists say these types of treatments could play a significant role against newly emerging SARS-CoV-2 variants.

Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants

IRF – Frederick
2/4/2021
13:04
110000
8.0
80
Imaging
#2021-01-B
SARS-CoV-2 UK B.1.1.7
XpixCal=3.848812
YpixCal=3.848812
Unit=nm
##fv3
4096
3008
7.0.1.147
Blank1
Blank2
##fv4